Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D brings in hefty $38mm for Alder Biopharmaceuticals

Executive Summary

Alder Biopharmaceuticals Inc. (developing therapeutics aimed at cancer, pain, and cardiovascular, autoimmune, and inflammatory diseases) has raised $38mm through its Series D financing led by first-time backer Novo Ventures, which adds a board member. Returning shareholders Sevin Rosen Funds, Ventures West, WRF Capital, HIG Ventures, Delphi Ventures, and TPG Biotech also participated. Funds will support ongoing clinical trials of its Phase II ALD518 in cancer and Phase I ALD403 for migraines, and preclinical development of ALD306 for dyslipidemia. The company raised $40mm in its January 2008 Series C round.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies